Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Last updated: February 10, 2025
Sponsor: Centers for Disease Control and Prevention
Overall Status: Active - Recruiting

Phase

2/3

Condition

Hiv

Lung Disease

Treatment

Pyrazinamide

Rifabutin

Delamanid

Clinical Study ID

NCT05766267
7406
  • Ages > 12
  • All Genders

Study Summary

The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week.

The first 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) (BMZRB) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb) (2 BMZRb/2 BMRb, Arm 1)

The Second 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus delamanid (D or DLM); (BMZD) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD, Arm 2)

The standard 26-week treatment control regimen which is two months of isoniazid, rifampin, ethambutol, and pyrazinamide (2HRZE) followed by four months of isoniazid and rifampin (4HR); (2HRZE/4HR, Arm 3)

Target enrollment is 288 male and female participants (96/arm). participants. Participants will be followed until 78 weeks post-randomization, or until the last enrolled participant completes 52 weeks post-randomization, whichever comes first.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Pulmonary tuberculosis with or without suspected or proven concomitantextrapulmonary tuberculosis outside the central nervous system or bones

  2. Acid-fast bacilli (AFB) seen in an expectorated sputum specimen at least 1+ orpositive GeneXpert (or GeneXpert Ultra) for M. tuberculosis, with semiquantitativeresults of "medium" or "high".

  3. Age ≥12 years

  4. Documentation of negative HIV status within the past 3 months prior to enrollment ordocumentation confirming HIV infection.

  5. For participants with HIV:

  6. current use of dolutegravir-based ART (Anti Retroviral Therapy), or ability andwillingness to start or transition to a dolutegravir-based antiretroviraltherapy regimen

  7. CD4 T cell count greater than or equal to 100 cells/mm3 based on testingperformed at or within 30 days prior to study enrollment

  8. Written informed consent/assent

  9. Karnofsky score of at least 60 ("requiring some help, can take care of most personalrequirements")

  10. A verifiable address or residence location that is readily accessible for visiting,and willingness to inform the study team of any change of address during thetreatment and follow-up period.

  11. For all women who have not undergone a surgical sterilization procedure or who donot meet the study definition of post-menopausal, a negative pregnancy test at orwithin seven (7) days prior to screening

  12. For all individuals of child-bearing potential who are not surgically sterilized,agreement to practice a reliable method of contraception (barrier method ornon-hormonal intrauterine device) or abstain from sexual activity that could lead topregnancy while receiving study drug treatment and for 30 days after stopping studytreatment

Exclusion

Exclusion Criteria:

  1. Pregnant or breast-feeding

  2. More than 5 days of tuberculosis treatment in the previous 6 months

  3. Previous treatment with any drug or combination of drugs known to have activityagainst M. tuberculosis (e.g., isoniazid, rifamycins, pyrazinamide, ethambutol,fluoroquinolones, etc.) for more than five days in the thirty days prior toenrollment

  4. Unable to take oral medications

  5. Hypersensitivity or previous intolerance to any of the study drugs

  6. Current or planned use of medications that have unacceptable drug-drug interactionswith any of the study drugs during study treatment

  7. Suspected or proven central nervous system tuberculosis

  8. Suspected or proven bone tuberculosis

  9. Screening ECG with QTcF >450 for men or >470 for women (Note: in case of hypokalemiaor hypomagnesemia, ECG can be repeated following electrolyte supplementation)

  10. Clinically significant ECG abnormality in the opinion of the site investigator,including but not limited to second or third degree atrioventricular (AV) block,prolongation of the QRS complex over 120 ms (in both male and female participants),or clinically important arrhythmia

  11. Current clinically relevant cardiovascular disorder in the opinion of the siteinvestigator, including but not limited to heart failure, coronary heart disease,arrhythmia, or tachyarrhythmia

  12. Known family history of Long QT Syndrome in a first-degree relative (i.e., parent,offspring, or sibling)

  13. History of aortic aneurysm or dissection

  14. Hepatic cirrhosis or other serious liver disease

  15. Other medical conditions, that, in the investigator's judgment, make studyparticipation not in the individual's best interest.

  16. Laboratory parameters done at or within 14 days prior to screening:

  17. Serum or plasma alanine aminotransferase greater than 3 times the upper limitof normal

  18. Serum or plasma total bilirubin greater than 2.5 times the upper limit ofnormal

  19. Serum creatinine > 2 times the upper limit of normal

  20. Platelet count < 75,000 cells/mm3

  21. Absolute neutrophil count <1,000 cells/mm3

  22. Serum or plasma potassium <3.5 meq/L (note: potassium may be repleted and testrepeated)

  23. Weight less than 40.0 kg

  24. Known or suspected resistance to isoniazid or rifamycins (by phenotypic or moleculartest)

  25. Previously enrolled in this study or currently enrolled in another therapeuticclinical trial that, in the investigator's judgment, would compromise studyintegrity or participant safety

  26. Current or planned incarceration or other involuntary detention.

Study Design

Total Participants: 288
Treatment Group(s): 8
Primary Treatment: Pyrazinamide
Phase: 2/3
Study Start date:
November 21, 2023
Estimated Completion Date:
December 31, 2027

Study Description

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Hypotheses:

  1. The time to sputum culture negative in liquid media will be shorter in the 17-week regimen of 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb) (2BMZRb/2 BMRb, Arm 1) than in the control arm.

  2. The time to sputum culture negative in liquid media will be shorter in the 17-week regimen of 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z); (BMZ) plus delamanid (D or DLM) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD, Arm 2) than in the control arm.

Phase: 3 Design: Open label, randomized clinical trial, initially in three treatment groups, with adaptive design allowing for introduction of novel regimens once they are clinically ready for testing Population: newly diagnosed with sputum smear positive or GeneXpert positive pulmonary tuberculosis, aged 12 years or older, with normal QTcF (QTc interval, Fridericia calculation) on screening ECG.

Number of Sites: 13 National and International sites, primarily sites of the Tuberculosis Trials Consortium Group. Study Duration: Duration per participant is approximately 78 weeks Description of Agent or Intervention: After written informed consent, participants will be randomized 1:1:1 to receive BMZRb, BMZD, or HRZE (Control treatment) as below

Arm 1(investigational regimen): 2 BMZRb/2 BMRb

  • Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus rifabutin (Rb), followed by

  • Nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb)

Arm 2 (investigational regimen): 2 BMZD/2 BMD

  • Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus delamanid (D or DLM) followed by

  • Nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM)

Arm 3 (Control regimen): 2 RHZE/4 RH

  • Eight weeks of daily treatment with rifampin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), (RHZE) followed by

  • Eighteen weeks of daily treatment with rifampin and isoniazid (RH)

Objectives

Primary Objectives:

  1. To compare the efficacy of 17-week regimen 8 weeks of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) followed by 9 weeks of bedaquiline (B or BDQ), moxifloxacin (M) and rifabutin (Rb) (2 BMZRb/2 BMRb) experimental regimen to the efficacy of standard treatment, using the intermediate endpoint of time to culture negative in liquid media.

  2. To compare the efficacy of 17-week regimen 8 weeks of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus delamanid (D or DLM) followed by 9 weeks of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD) experimental regimen to the efficacy of standard treatment, using the intermediate endpoint of time to culture negative in liquid media.

Secondary Objectives:

  1. To compare the proportion of participants with a grade 3 or higher adverse event in each experimental arm with the control arm

  2. To describe the proportion of participants experiencing lack of sustained cure during treatment or follow-up to 52 weeks in each experimental arm as compared to control and make predictions as to how these regimens would perform in future phase III trials.

  3. To compare the efficacy of each experimental regimen to the efficacy of standard treatment, using the intermediate endpoint of time to culture negative in solid media

  4. To compare the proportion of participants in each arm who convert liquid and solid sputum cultures to negative by (a) 8 weeks of treatment and (b) 12 weeks of treatment

  5. To describe the rate of all-cause study drug discontinuation in each arm

  6. To compare time to sputum culture positivity curves through 17 weeks in the Mycobacterial Growth Indicator Tube (Bactec MGIT960) across arms

  7. To describe the proportion of participants experiencing lack of sustained cure during treatment or follow-up up to 78 weeks in each experimental arm as compared to control and make predictions as to how these regimens would perform in future phase III trials.

  8. To describe the population PK of bedaquiline and its M2 metabolite, with or without rifabutin co-administration (PK#1)

  9. To conduct pharmacokinetic/pharmacodynamics study of the test drugs to determine relationships between pharmacokinetic parameters (AUC, Cmax) and outcome measures (time to culture negativity or rate of change in TTP) using non-linear mixed effects models, adjusting for key covariates that may affect outcomes (e.g. companion drugs, HIV status, cavitary disease) (PK#2)

Primary Endpoints:

  1. Time to sputum culture negative in liquid media

Secondary Endpoints:

  1. Proportion of participants with a Grade 3 or higher adverse event during 26 weeks from randomization

  2. Lack of sustained cure during treatment or follow-up to 52 weeks

  3. Time to sputum culture negative in solid media

  4. Proportion of participants with sputum culture negative by 8 weeks and by 12 weeks (solid and liquid media).

  5. All-cause study drug discontinuation

  6. The rate of change in time to sputum culture positivity (TTP) through 17 weeks in the Mycobacterial Growth Indicator Tube (Bactec MGIT960)

  7. Lack of sustained cure during treatment or follow-up to 78 weeks

  8. Population pharmacokinetics (PK) of bedaquiline, with or without rifabutin Pharmacokinetic/pharmacodynamic (PK/PD) relationship between test drug PK parameters and microbiologic outcomes

Connect with a study center

  • TBTC Site 77 CAB-V. Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou

    Cotonou,
    Benin

    Site Not Available

  • McGill University Health Centre

    Montréal,
    Canada

    Site Not Available

  • Vancouver, British Columbia Centre for Disease Control

    Vancouver,
    Canada

    Site Not Available

  • TBTC Site 45 Les Centres Gheskio (INLR)

    Port au Prince, Ouest HT6110
    Haiti

    Site Not Available

  • TBTC Site 67 GHESKIO centers IMIS

    Port-au-Prince, Ouest HT 6124
    Haiti

    Site Not Available

  • TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd

    Mowbray, Cape Town 7700
    South Africa

    Active - Recruiting

  • TBTC Site 30 Uganda-Case Western Reserve Research Collaboration

    Kampala,
    Uganda

    Active - Recruiting

  • TBTC Site 22 Denver Health and Hospitals

    Denver, Colorado 80204
    United States

    Site Not Available

  • TBTC Site 64 Brooklyn Campus of the VA NY Harbor Healthcare System

    Brooklyn, New York 11209
    United States

    Site Not Available

  • TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center

    Jackson Heights, New York 11372
    United States

    Site Not Available

  • TBTC Site 63 San Antonio VA Medical Center (South Texas Group)

    San Antonio, Texas 78229-4404
    United States

    Site Not Available

  • TBTC Site 26 Seattle & King County TB Control Program

    Seattle, Washington 98104
    United States

    Site Not Available

  • TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit

    Cần Thơ, Can Tho 70000
    Vietnam

    Site Not Available

  • TBTC Site 74 CAB-V. Ho Chi Minh City, Vietnam - District 6 TB Unit

    Ho Chi Minh City, Ho Chi Minh 70000
    Vietnam

    Site Not Available

  • TBTC Site 75 CAB-V. Ho Chi Minh City, Vietnam - Phoi Viet Respiratory Centre

    Ho Chi Minh City, Ho Chi Minh 70000
    Vietnam

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.